English | Français
English | Français
At iC BIOSOLUTIONS, we harness the power of acellular secretome therapy to address degenerative inflammatory diseases by targeting their underlying mechanisms, not just their symptoms.
Our mission is to deliver safe, effective, and scalable solutions that improve mobility, reduce pain, and transform quality of life, starting with animals and ultimately benefiting humans.
Equine arthritis is a major cause of chronic pain and disability in horses, a true scourge for equine health. Beyond its market potential, it offers a unique scientific advantage: Horses develop spontaneous, chronic joint degeneration that mirrors the biological, biomechanical, and inflammatory mechanisms seen in humans and other mammals.
Clinical Status
Starting with equine arthritis provides a powerful foundation for ICB001 because horses naturally develop osteoarthritis that closely mirrors the biological, biomechanical, and inflammatory processes seen in humans and other mammals.
This makes them an ideal model for demonstrating therapeutic efficacy and safety. ICB001’s mechanism, paracrine regenerative signaling, is highly conserved across species, and as an acellular, low-immunogenic secretome, it avoids compatibility issues.
The strong similarity between equine, canine, and human osteoarthritis ensures high predictive value, while its ability to target core inflammatory and regenerative pathways supports future applications in a wide range of chronic degenerative and inflammatory diseases.
Building on the success of ICB001, we aim to expand across species and indications, bringing transformative treatments to pets and humans.
Targeting chronic conditions in dogs and cats with scalable, field-ready therapies.
Long-term ambition to translate our therapy into human medicine, focusing on diseases where inflammation and degeneration intersect.
